Literature DB >> 10213268

Effect of alpha 1-acidic glycoprotein in the ascitic fluid of cancer patients on human NK cells: selective suppression of interferon-induced NK activation.

H Aso1, K Tamura, M T Rose, Y Tomioka, M Mizugaki, N Ishida.   

Abstract

The in vitro effect of C-AGP (pure alpha1-acid glycoprotein from the ascitic fluid of cancer patients) on NK cell cytotoxicity was tested using normal healthy human PBMC. C-AGP had no inhibitory effect on basal NK cell activity. C-AGP selectively suppressed the augmentation of NK cell activity by rIFNalphaA and rIFNgamma, but C-AGP did not prevent the NK activation by rIL-2. NK cells in PBMC treated with C-AGP for 12 h and then washed just once, to remove the C-AGP, fully recovered the ability to respond to rIFNalphaA. However, after the treatment of PBMC with C-AGP for 5 or 6 days, NK cells failed to respond to rIFNalphaA, in spite of washing to remove C-AGP from the cultures. Monocytes were necessary for the suppressive effect of C-AGP on rIFNalphaA activation of NK cells. Indomethacin restored the ability of NK cells to respond to rIFNalphaA in C-AGP-treated PBMC. These results suggest that monocytes are able to selectively suppress the response of NK cells to IFNs in the presence of, or following treatment with C-AGP.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10213268     DOI: 10.1023/a:1020236927814

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  31 in total

1.  Impaired NK response of cancer patients to IFN-alpha but not to IL-2: correlation with serum immunosuppressive acidic protein (IAP) and role of suppressor macrophage.

Authors:  H Aso; K Tamura; O Yoshie; T Nakamura; S Kikuchi; N Ishida
Journal:  Microbiol Immunol       Date:  1992       Impact factor: 1.955

2.  Immune function studies of alpha-1-acid glycoprotein.

Authors:  V K Singh
Journal:  Prog Clin Biol Res       Date:  1989

Review 3.  Drug binding to human alpha-1-acid glycoprotein in health and disease.

Authors:  J M Kremer; J Wilting; L H Janssen
Journal:  Pharmacol Rev       Date:  1988-03       Impact factor: 25.468

4.  Inhibition of murine natural killer cell activity by prostaglandins.

Authors:  M J Brunda; R B Herberman; H T Holden
Journal:  J Immunol       Date:  1980-06       Impact factor: 5.422

5.  Serum glycoproteins in cancer.

Authors:  H Bacchus
Journal:  Prog Clin Pathol       Date:  1975

6.  Interaction of an acute phase reactant, alpha 1-acid glycoprotein (orosomucoid), with the lymphoid cell surface: a model for non-specific immune suppression.

Authors:  D A Cheresh; D H Haynes; J A Distasio
Journal:  Immunology       Date:  1984-03       Impact factor: 7.397

7.  Isolation and characterization of an immunosuppressive acidic protein from ascitic fluids of cancer patients.

Authors:  K Tamura; Y Shibata; Y Matsuda; N Ishida
Journal:  Cancer Res       Date:  1981-08       Impact factor: 12.701

8.  Comparative in vivo and in vitro activation of human natural killer cells by two recombinant alpha-interferons differing in antiviral activity.

Authors:  B S Edwards; M J Hawkins; E C Borden
Journal:  Cancer Res       Date:  1984-07       Impact factor: 12.701

9.  Effects of immunosuppressive acidic protein on DMBA-induced pancreatic cancer in rats.

Authors:  S Matsuno; T Ejiri; M Kobari; H Yamauchi; T Sato
Journal:  Tohoku J Exp Med       Date:  1984-10       Impact factor: 1.848

10.  Immunosuppressive acidic protein in patients with gynecologic cancer.

Authors:  M Sawada; Y Okudaira; Y Matsui; Y Shimizu
Journal:  Cancer       Date:  1984-08-15       Impact factor: 6.860

View more
  2 in total

1.  Investigation of serum concentrations and immunohistochemical localization of α1-acid glycoprotein in tumor dogs.

Authors:  Masashi Yuki; Noboru Machida; Takayuki Sawano; Hiroshi Itoh
Journal:  Vet Res Commun       Date:  2010-10-21       Impact factor: 2.459

2.  Feline coronavirus--that enigmatic little critter.

Authors:  Diane D Addie
Journal:  Vet J       Date:  2004-01       Impact factor: 2.688

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.